BNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Burning Rock Biotech Ltd (BNR) is not a good buy for a beginner investor with a long-term strategy at this time. The stock has shown significant post-market decline (-12.71%), weak financial performance, and lacks positive trading signals or catalysts. The technical indicators do not suggest a strong entry point, and analysts have downgraded the stock. A hold position is recommended until more favorable conditions arise.
The MACD is negative (-0.876) and contracting, indicating bearish momentum. RSI is neutral at 30.442, and moving averages are converging, showing no clear trend. The stock is trading near its S2 support level (19.345), suggesting limited downside but no strong upward momentum.
Gross margin increased by 5.18% YoY in Q3 2025, indicating some operational efficiency improvement.
Post-market price dropped significantly (-12.71%). Net income and EPS dropped sharply (-53.12% and -54.29% YoY, respectively). Analysts have downgraded the stock, and there is no recent positive news or trading sentiment.
In Q3 2025, revenue increased by 2.31% YoY, but net income dropped significantly (-53.12% YoY) to -16.76 million, and EPS declined by -54.29% YoY to -0.16. Despite a slight improvement in gross margin (up 5.18% YoY), overall financial performance is weak.
Morgan Stanley downgraded the stock to Underweight with a reduced price target of EUR 50 (from EUR 63), citing caution on the chemical distribution sector. Berenberg also lowered its price target to EUR 48 (from EUR 51) and maintained a Hold rating, reflecting a lack of confidence in the stock's near-term performance.
